日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

DESTINY-Gastric05 phase III trial of first-line trastuzumab deruxtecan, chemotherapy, and pembrolizumab in HER2-positive gastric or gastroesophageal junction cancer

DESTINY-Gastric05 III期临床试验,评估一线曲妥珠单抗德鲁替康、化疗和帕博利珠单抗治疗HER2阳性胃癌或胃食管交界处癌的疗效。

Janjigian, Y Y; Smyth, E; Shen, L; Lee, J; Hoff, P M; Lonardi, S; Barrios, D; Kobayashi, K; Okuda, Y; Kamio, T; Shitara, K

Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer

拉罗替尼作为TRK融合癌患者一线治疗的疗效和安全性

Hong, D S; Xu, R-H; Shen, L; Dierselhuis, M P; Orbach, D; McDermott, R; Italiano, A; Tahara, M; Bernard-Gauthier, V; Neu, N; Mussi, C E; De La Cuesta, E; Laetsch, T W; Drilon, A

Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III KEYNOTE-590 study

帕博利珠单抗联合化疗对比单纯化疗治疗晚期食管癌:一项随机III期KEYNOTE-590研究的5年延长随访结果

Metges, J-P; Kato, K; Sun, J-M; Shen, L; Enzinger, P C; Adenis, A; Doi, T; Kojima, T; Li, Z; Kim, S-B; Cho, B C; Mansoor, W; Li, S-H; Sunpaweravong, P; Alsina, M; Buchschacher, G L Jr; Hara, H; Tsuji, A; Wu, J; Shah, S; Bhagia, P; Shah, M A

[Effects of ascites grading and the application of non-selective beta-blockers on the 1-year prognosis of acute-on-chronic liver failure]

[腹水分级和非选择性β受体阻滞剂应用对急性加慢性肝衰竭1年预后的影响]

Liu, W S; Shen, L J; He, X; Tian, H; Zhai, Q H; Li, D Z; Xin, S J; You, S L

[Bioinformatic analysis of venetoclax sensitivity and resistance mechanisms in acute myeloid leukemia]

[急性髓系白血病中维奈托克敏感性和耐药机制的生物信息学分析]

Yang, Y; Xu, C H; Wang, N; Fan, J T; Yang, D D; Niu, M M; Shen, L; Wang, H

[Research progress on early-stage primary biliary cholangitis accompanied by portal hypertension]

【早期原发性胆汁性胆管炎伴门静脉高压的研究进展】

Ma, L; Shen, L; Li, S X; Duan, W J; Jia, J D; You, H

Consensus statement on the use of systemic therapies in pancreatic ductal adenocarcinoma in Asia

亚洲胰腺导管腺癌全身治疗共识声明

Oh, D-Y; Shen, B; Satoi, S; Zhou, J; Kim, K-P; Choo, S P; Woo, S M; Chan, S L; Shen, L; Ikeda, M

Pembrolizumab with trastuzumab and chemotherapy for HER2-positive advanced gastric cancer: health-related quality-of-life analysis from the randomized KEYNOTE-811 trial

帕博利珠单抗联合曲妥珠单抗和化疗治疗HER2阳性晚期胃癌:来自随机KEYNOTE-811试验的健康相关生活质量分析

Janjigian, Y Y; Kawazoe, A; Xu, J; Lonardi, S; Metges, J-P; Wyrwicz, L S; Shen, L; Ostapenko, Y; Bilici, M; Lowery, M A; Valderrama, A; Guan, Y; Li, K; Shih, C-S; Rha, S Y

Tislelizumab versus chemotherapy as second-line treatment for European and North American patients with advanced or metastatic esophageal squamous cell carcinoma: a subgroup analysis of the randomized phase III RATIONALE-302 study

Tislelizumab 与化疗作为欧洲和北美晚期或转移性食管鳞状细胞癌患者二线治疗的比较:一项随机 III 期 RATIONALE-302 研究的亚组分析

Ajani, J; El Hajbi, F; Cunningham, D; Alsina, M; Thuss-Patience, P; Scagliotti, G V; Van den Eynde, M; Kim, S-B; Kato, K; Shen, L; Li, L; Ding, N; Shi, J; Barnes, G; Van Cutsem, E

[Upregulating KLF11 ameliorates intestinal inflammation in mice with 2, 4, 6-trinitrobenesulfonic acid-induced colitis by inhibiting the JAK2/STAT3 signaling pathway]

[上调 KLF11 通过抑制 JAK2/STAT3 信号通路改善 2,4,6-三硝基苯磺酸诱导的小鼠结肠炎的肠道炎症]

Xi, J; Zhang, M; Zhang, Y; Zhang, C; Zhang, Y; Wang, R; Shen, L; Li, J; Song, X